InvestorsHub Logo
Followers 15
Posts 240
Boards Moderated 0
Alias Born 01/31/2018

Re: humble howard post# 86755

Tuesday, 06/23/2020 5:16:05 PM

Tuesday, June 23, 2020 5:16:05 PM

Post# of 232952
Let's add Roche as a potential buyer. Actemra didn't do squat in coronavirus. In arthritis, it did well, but is past its peak. Their other immune drug, Xolair, faces that soon. A lot of people around with immunological backgrounds looking for something new to work on. Huge cancer franchise if they believe TNBC results. Big U.S. manufacturing ability for MABs through their Genentech unit. And with a $306B market cap, they could pay up.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News